201 related articles for article (PubMed ID: 19143566)
1. Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.
Markt P; Feldmann C; Rollinger JM; Raduner S; Schuster D; Kirchmair J; Distinto S; Spitzer GM; Wolber G; Laggner C; Altmann KH; Langer T; Gertsch J
J Med Chem; 2009 Jan; 52(2):369-78. PubMed ID: 19143566
[TBL] [Abstract][Full Text] [Related]
2. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor.
Salo OM; Raitio KH; Savinainen JR; Nevalainen T; Lahtela-Kakkonen M; Laitinen JT; Järvinen T; Poso A
J Med Chem; 2005 Nov; 48(23):7166-71. PubMed ID: 16279774
[TBL] [Abstract][Full Text] [Related]
3. 4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.
El Bakali J; Muccioli GG; Renault N; Pradal D; Body-Malapel M; Djouina M; Hamtiaux L; Andrzejak V; Desreumaux P; Chavatte P; Lambert DM; Millet R
J Med Chem; 2010 Nov; 53(22):7918-31. PubMed ID: 20979417
[TBL] [Abstract][Full Text] [Related]
4. Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists.
Worm K; Weaver DG; Green RC; Saeui CT; Dulay DM; Barker WM; Cassel JA; Stabley GJ; DeHaven RN; LaBuda CJ; Koblish M; Brogdon BL; Smith SA; Dolle RE
Bioorg Med Chem Lett; 2009 Sep; 19(17):5004-8. PubMed ID: 19646869
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies.
Lange JH; van der Neut MA; Wals HC; Kuil GD; Borst AJ; Mulder A; den Hartog AP; Zilaout H; Goutier W; van Stuivenberg HH; van Vliet BJ
Bioorg Med Chem Lett; 2010 Feb; 20(3):1084-9. PubMed ID: 20031412
[TBL] [Abstract][Full Text] [Related]
6. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
Muccioli GG; Wouters J; Charlier C; Scriba GK; Pizza T; Di Pace P; De Martino P; Poppitz W; Poupaert JH; Lambert DM
J Med Chem; 2006 Feb; 49(3):872-82. PubMed ID: 16451053
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of quinolinyl and isoquinolinyl phenyl ketones as novel agonists for the cannabinoid CB2 receptor.
Reux B; Nevalainen T; Raitio KH; Koskinen AM
Bioorg Med Chem; 2009 Jul; 17(13):4441-7. PubMed ID: 19477133
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel class of selective human CB1 inverse agonists.
Foloppe N; Allen NH; Bentley CH; Brooks TD; Kennett G; Knight AR; Leonardi S; Misra A; Monck NJ; Sellwood DM
Bioorg Med Chem Lett; 2008 Feb; 18(3):1199-206. PubMed ID: 18083560
[TBL] [Abstract][Full Text] [Related]
11. 7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as selective CB(2) cannabinoid receptor ligands: structural investigations around a novel class of full agonists.
Baraldi PG; Saponaro G; Moorman AR; Romagnoli R; Preti D; Baraldi S; Ruggiero E; Varani K; Targa M; Vincenzi F; Borea PA; Aghazadeh Tabrizi M
J Med Chem; 2012 Jul; 55(14):6608-23. PubMed ID: 22738271
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists.
Aghazadeh Tabrizi M; Baraldi PG; Saponaro G; Moorman AR; Romagnoli R; Preti D; Baraldi S; Ruggiero E; Tintori C; Tuccinardi T; Vincenzi F; Borea PA; Varani K
J Med Chem; 2013 Jun; 56(11):4482-96. PubMed ID: 23697626
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel serotonin 2C receptor ligands by sequential virtual screening.
Ahmed A; Choo H; Cho YS; Park WK; Pae AN
Bioorg Med Chem; 2009 Jul; 17(13):4559-68. PubMed ID: 19464901
[TBL] [Abstract][Full Text] [Related]
14. Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
Stern E; Muccioli GG; Bosier B; Hamtiaux L; Millet R; Poupaert JH; Hénichart JP; Depreux P; Goossens JF; Lambert DM
J Med Chem; 2007 Nov; 50(22):5471-84. PubMed ID: 17915849
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism.
Lange JH; Coolen HK; van der Neut MA; Borst AJ; Stork B; Verveer PC; Kruse CG
J Med Chem; 2010 Feb; 53(3):1338-46. PubMed ID: 20047331
[TBL] [Abstract][Full Text] [Related]
16. Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors.
Merighi S; Simioni C; Gessi S; Varani K; Borea PA
Biochem Pharmacol; 2010 Feb; 79(3):471-7. PubMed ID: 19766600
[TBL] [Abstract][Full Text] [Related]
17. GPCR structure-based virtual screening approach for CB2 antagonist search.
Chen JZ; Wang J; Xie XQ
J Chem Inf Model; 2007; 47(4):1626-37. PubMed ID: 17580929
[TBL] [Abstract][Full Text] [Related]
18. Structural modifications of the cannabinoid side chain towards C3-aryl and 1',1'-cycloalkyl-1'-cyano cannabinoids.
Papahatjis DP; Nahmias VR; Andreou T; Fan P; Makriyannis A
Bioorg Med Chem Lett; 2006 Mar; 16(6):1616-20. PubMed ID: 16387492
[TBL] [Abstract][Full Text] [Related]
19. 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists.
Muccioli GG; Wouters J; Scriba GK; Poppitz W; Poupaert JH; Lambert DM
J Med Chem; 2005 Nov; 48(23):7486-90. PubMed ID: 16279809
[TBL] [Abstract][Full Text] [Related]
20. Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
Laggner C; Schieferer C; Fiechtner B; Poles G; Hoffmann RD; Glossmann H; Langer T; Moebius FF
J Med Chem; 2005 Jul; 48(15):4754-64. PubMed ID: 16033255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
